{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:08:16Z","timestamp":1778857696850,"version":"3.51.4"},"posted":{"date-parts":[[2026,5,13]]},"group-title":"Psychiatry and Clinical Psychology","reference-count":66,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The mechanisms underlying pharmacological treatments for stimulant use disorders are poorly understood. This study examined whether changes in craving, depressive symptoms, and\/or impulsivity mediate treatment effect in pharmacotherapy with combined naltrexone and bupropion for methamphetamine use disorder.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study was based on secondary analysis of data from the Accelerated Development of Additive Pharmacotherapy Treatment for methamphetamine disorder (ADAPT-2) trial which randomized adults with methamphetamine use disorder to combined treatment with injectable naltrexone (380 mg every three weeks) plus oral bupropion (450 mg daily) versus placebo. A total of 403 adults with methamphetamine use disorder participated in the first Stage; 225 of first Stage participants in the placebo arm who did not respond to treatment were re-randomized in the second Stage. Mediation effects were examined using longitudinal multi-level structural equation modeling.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Naltrexone-bupropion treatment was associated with decreases in drug use, craving, depressive symptoms, and impulsivity. The indirect effect of treatment through change in craving was significant (self-reported use=-0.21, 95% Credible Interval [CrI]=-0.35, \u22120.09; drug screen-ascertained use=-0.36, 95% CrI=-0.63, \u22120.16). Change in craving mediated 56% of the treatment effect on self-reported use and 45% of the effect on drug screen-ascertained use. Estimates for mediated effects for depressive symptoms and impulsivity were smaller in magnitude and non-significant.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Reduction in craving mediates the effect of naltrexone-bupropion pharmacotherapy in methamphetamine use disorder. Craving may serve as a surrogate measure of treatment efficacy in short-term trials and help identify promising candidate medications to be tested in larger and longer-term trials.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Trial Registration<\/jats:title>\n                  <jats:p>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    number:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03078075\">NCT03078075<\/jats:ext-link>\n                    .\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.05.09.26352807","type":"posted-content","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:15:15Z","timestamp":1778688915000},"source":"Crossref","is-referenced-by-count":0,"title":["Mediators of Treatment Response in Clinical Trial of Naltrexone and Bupropion for Methamphetamine Use Disorder: A Longitudinal Mediation Analysis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-4043","authenticated-orcid":false,"given":"Ramin","family":"Mojtabai","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Tulane Medical School, New Orleans, LA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Susukida","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trang Quynh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Bergeria","sequence":"additional","affiliation":[{"name":"Kahlert Institute for Addiction Medicine, University of Maryland School of Medicine, Baltimore MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Tulane Medical School, New Orleans, LA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Kahlert Institute for Addiction Medicine, University of Maryland School of Medicine, Baltimore MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Amin-Esmaeili","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"1","key":"2026051507150711000_2026.05.09.26352807v1.1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s13063-019-3554-6","article-title":"A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving","volume":"20","year":"2019","journal-title":"Trials"},{"key":"2026051507150711000_2026.05.09.26352807v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.07.007"},{"key":"2026051507150711000_2026.05.09.26352807v1.3","unstructured":"Asparouhov T , Muthen, B. (2010) Bayesian analysis using Mplus: Technical implementation. Reportno. Report Number|, Date. Place Published|: Institution|."},{"key":"2026051507150711000_2026.05.09.26352807v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111018"},{"issue":"5","key":"2026051507150711000_2026.05.09.26352807v1.5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/abm\/kaaa066","article-title":"Understanding Between-Person Interventions With Time-Intensive Longitudinal Outcome Data: Longitudinal Mediation Analyses","volume":"55","year":"2021","journal-title":"Ann Behav Med"},{"issue":"8","key":"2026051507150711000_2026.05.09.26352807v1.6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/15563650.2020.1861287","article-title":"Methamphetamine exposures reported to United States poison control centers, 2000\u20132019","volume":"59","year":"2021","journal-title":"Clinical Toxicology"},{"issue":"3","key":"2026051507150711000_2026.05.09.26352807v1.7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial","volume":"77","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301481"},{"issue":"11","key":"2026051507150711000_2026.05.09.26352807v1.9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/07067437241262967","article-title":"Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: Efficacite et innocuite du modafinil pour le traitement des troubles lies a l\u2019usage de stimulants de type amphetamine : revue systematique et meta-analyse d\u2019essais randomises controles par placebo","volume":"69","year":"2024","journal-title":"Can J Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.10","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.68.1.134"},{"issue":"11","key":"2026051507150711000_2026.05.09.26352807v1.11","first-page":"2433","article-title":"Role of modafinil in the treatment of patients with methamphetamine dependence: An update on randomized, controlled clinical trial","volume":"19","year":"2020","journal-title":"Tropical Journal of Pharmaceutical Research"},{"issue":"1","key":"2026051507150711000_2026.05.09.26352807v1.12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41386-023-01600-9","article-title":"How should we design future mechanistic and\/or efficacy clinical trials?","volume":"49","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"2026051507150711000_2026.05.09.26352807v1.13","doi-asserted-by":"publisher","DOI":"10.1159\/000069738"},{"key":"2026051507150711000_2026.05.09.26352807v1.14","first-page":"63","article-title":"How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: Craving and ongoing methamphetamine use","volume":"1","author":"Singleton EG and The Methamphetamine Treatment Project Corporate A","year":"2009","journal-title":"Subst Abuse"},{"issue":"10","key":"2026051507150711000_2026.05.09.26352807v1.15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamapsychiatry.2016.2157","article-title":"Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial","volume":"73","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21121207"},{"key":"2026051507150711000_2026.05.09.26352807v1.17","unstructured":"Geiser C (2021) Longitudinal structural equation modeling with Mplus : a latent state-trait perspective. New York: The Guilford Press."},{"key":"2026051507150711000_2026.05.09.26352807v1.18","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0b013e31819db6fe"},{"issue":"6","key":"2026051507150711000_2026.05.09.26352807v1.19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1080\/00273171.2018.1446819","article-title":"At the Frontiers of Modeling Intensive Longitudinal Data: Dynamic Structural Equation Models for the Affective Measurements from the COGITO Study","volume":"53","year":"2018","journal-title":"Multivariate Behav Res"},{"issue":"12","key":"2026051507150711000_2026.05.09.26352807v1.20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults","volume":"78","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00217-9"},{"key":"2026051507150711000_2026.05.09.26352807v1.22","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12060782"},{"key":"2026051507150711000_2026.05.09.26352807v1.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0494-0"},{"key":"2026051507150711000_2026.05.09.26352807v1.24","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001639"},{"key":"2026051507150711000_2026.05.09.26352807v1.25","doi-asserted-by":"crossref","first-page":"208955","DOI":"10.1016\/j.josat.2023.208955","article-title":"Risk factors for relapse among methamphetamine users receiving a joint legal-medical treatment program as a diversion intervention: A one-year follow-up study","volume":"151","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"2026051507150711000_2026.05.09.26352807v1.26","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001538"},{"key":"2026051507150711000_2026.05.09.26352807v1.27","first-page":"3","article-title":"Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial","volume":"86","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.28","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14688"},{"key":"2026051507150711000_2026.05.09.26352807v1.29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2019.04.010","article-title":"Effectiveness of methamphetamine abuse treatment: Predictors of treatment completion and comparison of two residential treatment programs","volume":"201","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2026051507150711000_2026.05.09.26352807v1.30","unstructured":"Kish L (1965) Survey sampling. New York,: J. Wiley."},{"issue":"11","key":"2026051507150711000_2026.05.09.26352807v1.31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamapsychiatry.2019.1839","article-title":"Time to Reconsider the Role of Craving in Opioid Use Disorder","volume":"76","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"issue":"4","key":"2026051507150711000_2026.05.09.26352807v1.33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00132576-200211000-00005","article-title":"A comparison of single-item visual analog scales with a multiitem likert-type scale for assessment of cocaine craving in persons with bipolar disorder","volume":"1","year":"2002","journal-title":"Addictive Disorders & Their Treatment"},{"issue":"1","key":"2026051507150711000_2026.05.09.26352807v1.34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1465-3362.2012.00473.x","article-title":"A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes","volume":"32","year":"2013","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"2026051507150711000_2026.05.09.26352807v1.35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/dar.13670","article-title":"Methamphetamine exposure and depression-A systematic review and meta-analysis","volume":"42","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"2026051507150711000_2026.05.09.26352807v1.36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jad.2022.09.064","article-title":"Depression in Chinese men with methamphetamine dependence: Prevalence, correlates and relationship with alexithymia","volume":"319","year":"2022","journal-title":"J Affect Disord"},{"key":"2026051507150711000_2026.05.09.26352807v1.37","doi-asserted-by":"publisher","DOI":"10.1111\/add.12608"},{"key":"2026051507150711000_2026.05.09.26352807v1.38","doi-asserted-by":"crossref","first-page":"842947","DOI":"10.3389\/fpsyt.2022.842947","article-title":"Intermittent Theta Burst Stimulation vs. High-Frequency Repetitive Transcranial Magnetic Stimulation in the Treatment of Methamphetamine Patients","volume":"13","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.39","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1017\/S0033291725101165","article-title":"Altered morphological cortical thickness and disrupted network attributes and its relationships with drug use characteristics and impulsivity in abstinent male subjects with methamphetamine use disorder","volume":"55","year":"2025","journal-title":"Psychol Med"},{"key":"2026051507150711000_2026.05.09.26352807v1.40","doi-asserted-by":"publisher","DOI":"10.1177\/0193841X9301700202"},{"key":"2026051507150711000_2026.05.09.26352807v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.12.004"},{"key":"2026051507150711000_2026.05.09.26352807v1.42","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810250089015"},{"key":"2026051507150711000_2026.05.09.26352807v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.10.002"},{"key":"2026051507150711000_2026.05.09.26352807v1.44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.01.034","article-title":"The relationship between impulsivity and methamphetamine use severity in a community sample","volume":"187","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"2026051507150711000_2026.05.09.26352807v1.45","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/add.16610","article-title":"Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder","volume":"119","year":"2024","journal-title":"Addiction"},{"issue":"2","key":"2026051507150711000_2026.05.09.26352807v1.46","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jad.2013.07.036","article-title":"Dynamic indices of methamphetamine dependence and HIV infection predict fluctuations in affective distress: a five-year longitudinal analysis","volume":"151","year":"2013","journal-title":"J Affect Disord"},{"key":"2026051507150711000_2026.05.09.26352807v1.47","doi-asserted-by":"crossref","first-page":"971825","DOI":"10.3389\/fpsyt.2022.971825","article-title":"Associations of executive function and age of first use of methamphetamine with methamphetamine relapse","volume":"13","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.48","doi-asserted-by":"crossref","first-page":"109295","DOI":"10.1016\/j.drugalcdep.2022.109295","article-title":"Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis","volume":"232","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"2026051507150711000_2026.05.09.26352807v1.49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/10550490802268462","article-title":"Association between psychiatric symptoms and craving in methamphetamine users","volume":"17","year":"2008","journal-title":"Am J Addict"},{"key":"2026051507150711000_2026.05.09.26352807v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300979"},{"issue":"9","key":"2026051507150711000_2026.05.09.26352807v1.51","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","article-title":"Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review","volume":"77","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2026051507150711000_2026.05.09.26352807v1.52","doi-asserted-by":"publisher","DOI":"10.1177\/0049124112460380"},{"key":"2026051507150711000_2026.05.09.26352807v1.53","doi-asserted-by":"publisher","DOI":"10.1037\/a0020141"},{"issue":"10","key":"2026051507150711000_2026.05.09.26352807v1.54","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/npp.2015.83","article-title":"The effects of naltrexone on subjective response to methamphetamine in a clinical sample: A double-blind, placebo-controlled laboratory study","volume":"40","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"2026051507150711000_2026.05.09.26352807v1.55","doi-asserted-by":"crossref","first-page":"209189","DOI":"10.1016\/j.josat.2023.209189","article-title":"Predictive role of impulsivity, anxiety, and depression in the efficacy of intermittent theta burst transcranial magnetic stimulation modalities for treating methamphetamine use disorder: A randomized clinical trial","volume":"156","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"13","key":"2026051507150711000_2026.05.09.26352807v1.56","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s00213-017-4607-8","article-title":"Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder","volume":"234","year":"2017","journal-title":"Psychopharmacology (Berl"},{"key":"2026051507150711000_2026.05.09.26352807v1.57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02437.x"},{"issue":"3","key":"2026051507150711000_2026.05.09.26352807v1.58","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2008.03.028","article-title":"Effect of drug-paired exteroceptive stimulus presentations on methamphetamine reinstatement in rats","volume":"90","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"2026051507150711000_2026.05.09.26352807v1.59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1747-597X-7-44","article-title":"Negative moods correlate with craving in female methamphetamine users enrolled in compulsory detoxification","volume":"7","year":"2012","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2026051507150711000_2026.05.09.26352807v1.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.03.005"},{"key":"2026051507150711000_2026.05.09.26352807v1.61","doi-asserted-by":"crossref","unstructured":"Sobell LC , Sobell, M.B. (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ , Allen, J.P. (39ed) Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press, pp.41\u201372.","DOI":"10.1007\/978-1-4612-0357-5_3"},{"issue":"25-27","key":"2026051507150711000_2026.05.09.26352807v1.62","doi-asserted-by":"crossref","first-page":"e70319","DOI":"10.1002\/sim.70319","article-title":"Estimating Causal Treatment Effects in the Sequential Parallel Comparison Design (SPCD)","volume":"44","year":"2025","journal-title":"Stat Med"},{"key":"2026051507150711000_2026.05.09.26352807v1.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2020214"},{"key":"2026051507150711000_2026.05.09.26352807v1.64","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2147\/NDT.S406909","article-title":"Psychometrics of the Concise Health Risk Tracking Self-Report (CHRT-SR(16)) Assessment of Suicidality in a Sample of Adults with Moderate to Severe Methamphetamine Use Disorder: Findings from the ADAPT-2 Randomized Trial","volume":"19","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026051507150711000_2026.05.09.26352807v1.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2010.12.022"},{"key":"2026051507150711000_2026.05.09.26352807v1.66","unstructured":"Geiser C (2021) Longitudinal structural equation modeling with Mplus : a latent state-trait perspective. New York: The Guilford Press."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.05.09.26352807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:15:19Z","timestamp":1778854519000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.05.09.26352807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":66,"URL":"https:\/\/doi.org\/10.64898\/2026.05.09.26352807","relation":{},"subject":[],"published":{"date-parts":[[2026,5,13]]},"subtype":"preprint"}}